Fund shareholders of REVOLUTION MEDICINES INC
ISIN US76155X1000 · United States · LEI 549300JU3X0LBCQ65892
- Fund shareholders
- 512
- Of which ETFs
- 120 392 other funds
- Value held
- ≈ 11.1B $ 11B $ · 404.1M SEK · 677.8K €
- Share of capital
- 28.7 % of 214.3M shares on Jul 31, 2026
This issuer has other securities: REVOLUTION MEDICINES INC WTS 12/26 (US76155X1182)
512 funds hold this company. This table lists the 511 that declare it in a regulatory filing. 1 more fund publishes its holdings in its own report. The “Fund reports” tab lists it, with its weight.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Sector Rotation Fund Meeder Funds | 39 | 7.3K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| T. Rowe Price Active Core U.S. Equity ETF T. Rowe Price Exchange-Traded Funds, Inc. | 35 | 6.6K $ | 0.05 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SA Schroders VCP Global Allocation Portfolio SUNAMERICA SERIES TRUST | 34 | 6.4K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| iShares Enhanced Large Cap Core Active ETF BlackRock ETF Trust | 32 | 6K $ | 0.04 % | 0.00 % | as of Jul 31, 2026 ↗ |
| AQR Multi-Asset Fund AQR Funds | 26 | 4.9K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Milliman Healthcare Inflation Plus ETF Milliman Funds Trust | 22 | 4.1K $ | 0.41 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Defiance Ksm Tipranks Analyst ETF Tidal Trust II | 16 | 3K $ | 0.72 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Ruk Strategic Growth ETF Advisor Managed Portfolios | 14 | 2.6K $ | 0.12 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIP Hedged Equity Portfolio Variable Insurance Products Fund VI | 12 | 2.2K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Milliman Healthcare Inflation Guard ETF Milliman Funds Trust | 9 | 1.7K $ | 0.17 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 677.8K € | 0.82 % | as of Dec 31, 2025 ↗ |
Funds that publish their own holdings
| Fund | Weight in fund | |
|---|---|---|
| Pictet - Biotech Pictet Asset Management (Europe) S.A. | 2.13 % | as of Sep 30, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Tema Oncology ETF Tema ETF Trust | 7.73 % | as of May 31, 2026 ↗ |
| VanEck Biotech ETF VanEck ETF Trust | 5.27 % | as of Jun 30, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 4.94 % | as of Jul 31, 2026 ↗ |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 4.55 % | as of Jul 31, 2026 ↗ |
| Marsico Midcap Growth Focus Fund MARSICO INVESTMENT FUND | 4.38 % | as of Jun 30, 2026 ↗ |
| HealthInvest Small & Mid Cap Healthcare Atle Fund Management AB | 4.13 % | as of Mar 31, 2026 ↗ |
| Corgi Genomics & Precision Medicine ETF Corgi ETF Trust I | 3.74 % | as of Jun 30, 2026 ↗ |
| NICHOLAS PARTNERS SMALL CAP GROWTH FUND ADVISORS' INNER CIRCLE III | 3.69 % | as of Jun 30, 2026 ↗ |
| Tema Heart & Health ETF Tema ETF Trust | 3.33 % | as of May 31, 2026 ↗ |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 3.02 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 492 | +92 | 60,988,660 | +27.2 % |
| 2026Q2 | 400 | +41 | 47,949,343 | -6.1 % |
| 2026Q1 | 359 | +41 | 51,041,234 | -8.6 % |
| 2025Q4 | 318 | -18 | 55,857,845 | -6.5 % |
| 2025Q3 | 336 | +10 | 59,732,762 | -7.8 % |
| 2025Q2 | 326 | +4 | 64,794,405 | +3.7 % |
| 2025Q1 | 322 | +9 | 62,505,392 | +5.6 % |
| 2024Q4 | 313 | +26 | 59,209,688 | +5.5 % |
| 2024Q3 | 287 | +20 | 56,129,869 | +4.9 % |
| 2024Q2 | 267 | +18 | 53,490,879 | +17.6 % |
| 2024Q1 | 249 | +26 | 45,498,077 | +12.7 % |
| 2023Q4 | 223 | 40,365,735 |
Institutional managers
503 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 13,604,796 | 1.3B $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 11,212,706 | 1.1B $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 9,766,496 | 949.5M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 9,555,357 | 929.3M $ | as of Mar 31, 2026 |
| FMR LLC | 8,464,314 | 823.2M $ | as of Mar 31, 2026 |
| Nextech Invest, Ltd. | 7,601,087 | 739.2M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 6,655,703 | 647.3M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 6,027,819 | 586.2M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,475,611 | 532.5M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 4,402,662 | 428.2M $ | as of Mar 31, 2026 |
| UBS Group AG | 4,386,791 | 426.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,338,142 | 323.9M $ | as of Mar 31, 2026 |
| Alphabet Inc. | 3,292,525 | 320.2M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,232,213 | 314.3K $ | as of Mar 31, 2026 |
| BVF INC/IL | 2,856,782 | 277.8M $ | as of Mar 31, 2026 |
| Casdin Capital, LLC | 2,577,333 | 250.6M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 2,506,570 | 243.8M $ | as of Mar 31, 2026 |
| Holocene Advisors, LP | 2,468,644 | 240.1M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 2,375,000 | 231M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 2,344,444 | 228M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,297,000 | 223.4M $ | as of Mar 31, 2026 |
| Darwin Global Management, Ltd. | 2,211,018 | 205M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 2,185,500 | 212.5M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 2,000,000 | 194.5M $ | as of Mar 31, 2026 |
| Alyeska Investment Group, L.P. | 1,885,821 | 183.4M $ | as of Mar 31, 2026 |
Declared shareholders of REVOLUTION MEDICINES INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Farallon Capital Management, L.L.C. and 28 others | 6.40 % | 13,564,149 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 5.70 % | 12,201,395 | as of Jun 30, 2026 · SCHEDULE 13G |
| Baker Bros. Advisors LP and 3 others | 5.30 % | 11,443,357 | as of Jun 30, 2026 · SCHEDULE 13G |
| JANUS HENDERSON GROUP Ltd. | 5.10 % | 10,736,145 | as of Jun 30, 2026 · SCHEDULE 13G |
Funds holding the debt of REVOLUTION MEDICINES INC
26 funds declare 26 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of REVOLUTION MEDICINES INC". https://titelia.com/en/stocks/revolution-medicines-inc-US76155X1000